WO2008103754A2 - Implant intraoculaire esthétique - Google Patents

Implant intraoculaire esthétique Download PDF

Info

Publication number
WO2008103754A2
WO2008103754A2 PCT/US2008/054458 US2008054458W WO2008103754A2 WO 2008103754 A2 WO2008103754 A2 WO 2008103754A2 US 2008054458 W US2008054458 W US 2008054458W WO 2008103754 A2 WO2008103754 A2 WO 2008103754A2
Authority
WO
WIPO (PCT)
Prior art keywords
implant
reactive
side wall
iris
vat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/054458
Other languages
English (en)
Other versions
WO2008103754A3 (fr
Inventor
Janet C. Tseng
Yichieh Shiuey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008103754A2 publication Critical patent/WO2008103754A2/fr
Publication of WO2008103754A3 publication Critical patent/WO2008103754A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2/1602—Corrective lenses for use in addition to the natural lenses of the eyes or for pseudo-phakic eyes
    • A61F2/1605—Anterior chamber lenses for use in addition to the natural lenses of the eyes, e.g. iris fixated, iris floating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/142—Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants

Definitions

  • the present invention relates generally to intraocular implants and more specifically to an implant having a tapered configuration that can be implanted between a cornea and an iris and can be dyed to impart a color to the iris.
  • U.S. Pat. No. 5,628,797 describes an intraocular implant, which is disposed in the anterior chamber.
  • the implant comprises a transparent material, particularly a rigid transparent plastics such as polymethacrylate (PMMA).
  • PMMA polymethacrylate
  • the implant includes two ring halves, which can be combined to a closed ring, wherein the resulting annular surface rests on the pupil of the eye.
  • This type of implant would be difficult to manufacture because it requires mechanical fittings which are microscopic in scale.
  • Another disadvantage is that the implant requires assembly within the anterior chamber, which is a very small space, typically having a maximum height less than 4 mm. This limited space would make it extremely difficult for the surgeon to manipulate the interlocking pieces.
  • U.S. Pat No. 7,037,337 (Carriazo) describes a flexible intraocular implant which is an annular ring which contains openings within the ring through which iris tissue is pinched in order to achieve attachment of the implant to the iris.
  • the pinching nature of the attachments will damage the iris, potentially causing localized atrophy. In addition, it may cause ulceris, which is painful and potentially vision threatening.
  • the implants are described as annular or ring like.
  • a flat annular shape is not ideal for an iris implant because in the typical normal human eye the iris is angulated upward by the presence of the crystalline lens. Therefore, an annular shape of the implant would mean that the implant would have to be touching the iris which causes chafing and irritation, especially because of the dynamic nature of the iris diaphragm.
  • an intraocular implant comprises a continuous sidewall having a top and a bottom.
  • the sidewall is adapted to be implanted in an anterior chamber under the cornea and above the lens in an eye.
  • the implant will be adapted to reside or rest over the iris with minimum touching of the iris. This positioning may be achieved using an implant which is tapered from the bottom toward the top.
  • a conical or dome-shaped implant having a lower peripheral lip or edge which engages the outer edge of the iris near the junction with the cornea and is angled upwardly from the edge, typically at an angle in the range from 1° to 60°, preferably from 1° to 45°.
  • the top of the implant will typically be open, but in some embodiments could include a lens for corrective or other purposes. While in some instances, the implant may be clear (without color), in most cases the implant will be dyed or otherwise colored in order to provide for aesthetic coloring or re-coloring of the iris.
  • Methods according to the present invention comprise implanting an implant interior to the iris, where the implant has a tapered geometry that reduces contact with the iris.
  • the tapered geometry will provide a peripheral edge which rests against the outer periphery of the iris near the junction with the cornea.
  • the continuous wall of the implant will be angled upwardly, as discussed above, so that contact with the iris is eliminated or minimized.
  • the implant will be made from a biocompatible polymer which can be rolled or otherwise reduced in profile to permit implantation through a small incision in the eye.
  • the aesthetic implant would be manufactured from acrylic polymers, silicone polymers, or collagen polymers.
  • the implant could be manufactured from a polymer which comprises one or more compounds selected from the group consisting of polyurethanes, poly(2-hydroxyethylmethacrylate), polyvinylpyrrolidone, polyglycerolmethacrylate, polyvinyl alcohol, polyethylene glycol, polymethacrylic acid, polyfluorocarbons, and polymers with phosphocholine.
  • the polymer composition could be either hydrophilic or hydrophobic.
  • the polymer may be a hydrogel or non-hydrogel.
  • the dyes listed hereinafter may be introduced into the polymers of the implant in conventional manners.
  • the implant of the present invention may comprise pertinent features which improve the performance.
  • footpads that project outwardly from the lower periphery of the implant may be provided in order to stabilize the implantation, hi preferred aspects the implant would be designed so that footpads would engage either the scleral spur or the iris root, both of which are relatively insensitive structures.
  • fenestrations or openings may be provided through the sidewall to permit aqueous flow through the implant to improve nourishment of the interior of the eye.
  • lenses may optionally be positioned within the upper opening of the implant to provide for vision correction or the like.
  • Fig. 1 is a cross-sectional view of a normal eye which demonstrates the normal upward angulation ⁇ of the iris I in most humans because of the presence of the crystalline lens L.
  • C is the cornea.
  • V is the vitreous jelly.
  • FIG. 2 shows a cross-sectional view of a prior art annular implant A which touches the iris at T which may cause chafing and inflammation with movements of the iris and pupil.
  • O is the opening of the annular implant.
  • FIG. 3 shows a cross-sectional view of an implant N according to the present invention.
  • the implant N minimizes touching of intraocular structures because of its truncated cone or truncated dome shape. Note how the implant only touches the anterior chamber angle. O' is the top opening in the new implant.
  • Fig. 4 shows a three dimensional view of the new implant.
  • the hatched line shows the back portion of the bottom of the implant N constructed in accordance with the principle of the present invention.
  • An opening O' at the top of the implant overlies the pupil.
  • a bottom opening O" is located at the bottom of the implant.
  • the shape of the implant is generally tapered from the bottom toward the top, typically as a truncated cone or truncated dome.
  • angle ⁇ ' will be such that it will generally correspond to the angle of the iris and cornea, so as to avoid touching intraocular structures. In preferred aspects, angle ⁇ ' will be between 1° and 60°, preferably being in the range from 1° to 45°.
  • S is the side wall of the implant.
  • Figs. 5 and 5 A show a top view of an implant N' of the present invention.
  • the top opening is seen as O 1 .
  • the side S of the implant receives the coloration. Footplates 10 will allow alternative fixation of the lens in the anterior chamber angle.
  • fenestrations 20 are shown which will allow normal flow of aqueous to nourish the interior of the eye.
  • a faceted implant is shown in Fig. 5 A.
  • An intraocular implant N' for the anterior chamber is shaped like a truncated cone or truncated dome, wherein the top of the truncated cone or truncated dome is either physically open or is covered partially or fully by a lens. While shown as a regular cone with a continuous or smooth side, the cone could also have flat faces or facets F and be a truncated pyramid rather than a simple cone (Fig. 5A). The structure could also include both flat and rounded portions so long as the total surface tapers from the base to the top. The bottom of the truncated cone, truncated dome or other tapered structure is physically open.
  • the shape of the implant be a truncated cone or truncated dome or be otherwise tapered in order to allow the implant to have minimal contact with intraocular structures.
  • the angle(s) of the side(s) of the truncated structure is such that it allows clearance or set back of the implant from the iris itself and from the cornea. Contact between the implant and the intraocular structures is preferably limited to the relatively insensitive anterior chamber angle or iris root.
  • the shape of the implant as being either a truncated cone or truncated dome, our invention also includes shapes which are similar to either truncated domes or cones, which allows the implant to only touch the relatively insensitive anterior chamber angle or iris root.
  • the bottom of the implant does not need to be perfectly round. In fact, a slight ovality would be preferable for the shape of the bottom of the implant to match the slight ovality of the cornea.
  • the implant would be made of a biocompatible flexible material which may be colored with biocompatible color additives.
  • biocompatible color additives may include, but are not limited to one or more of the following:
  • Vat Orange 2-[(2,5-Diethoxy- 4-[(4- methylphenyl)thiol] phenyl)azo] -1,3,5-benzenetriol, C.I. Vat brown 1: 16,23- Dihydrodinaphtho [2,3-a:2',3'-i] naphth [2',3':6,7] indolo [2,3-c] carbazole- 5,10,15,17,22,24- hexone, C.I. Vat yellow 3: N,N'-(9,10-Dihydro- 9,10-dioxo- 1,5-anthracenediyl) bisbenzamide, C.I.
  • Vat blue 6 7,16-Dichloro- 6,15-dihydro- 5,9,14,18-anthrazinetetrone
  • C.I. Vat green 1 16,17-Dimethoxydinaphtho (l,2,3-cd:3',2',l'-mi) perylene-5,10-dione
  • Poly(hydroxyethyl methacrylate) -dye copolymers including one or more of C.I. Reactive black 5, C.I. Reactive blue 21, C.I. Reactive orange 78, C.I. Reactive yellow 15, C.I. Reactive blue 19, C.I. Reactive blue 4, C.I. Reactive red 11, C.I. Reactive yellow 86, C.I.
  • Reactive blue 19 CI. Reactive blue 21
  • Mica-based pearlescent pigments (Phthalocyaninato(2-)) copper, D&C Green No. 6, D&C Red No. 17, D&C Violet No. and D&C Yellow No. 10.
  • the implant would have at least two footplates 10, more preferably three, and still more preferably four footplates at the bottom of the truncated cone.
  • the footplates 10 allow gentle positioning within the anterior chamber angle or against the iris root.
  • the presence of footplates would further decrease the amount of contact between the implant and the intraocular structures. See Fig. 5.
  • the presence of footplates is advantageous because it allows stable fixation of the implant while causing the least possible amount of irritation to the eye.
  • fenestrations or openings in the implant which would allow aqueous to flow normally through the implant to allow nourishment of the interior of the eye.
  • the implant would include a lens in the center of the implant.
  • the system would include an implant inserter that would allow the implant to be reversibly deformed such that it could be injected through a small incision in the eye.
  • the incision would be less than 3 mm, more preferably the incision would be less than 1 mm.
  • the system would include a software program which would help determine the best shape and dimensions of the implant for an individual eye.
  • the software program would take data obtained from imaging studies of an individual eye and use this data to determine the shape and dimensions of the implant which will minimize contact with intraocular structures.
  • Types of imaging studies which could be used for this purpose include, but are not limited to: B-scan ultrasound, anterior segment optical coherence tomography, radiographic computed tomography and magnetic resonance imaging.
  • the software program would be installed on the computer system of the imaging apparatus and the dimensional data of the eye would automatically be imported into the software program.
  • This dimensional data could include, but is not limited to the angle to angle distance for 360 degrees and the angle of the iris relative to the plane of the scleral spur or some other fixed plane for 360 degrees.
  • the dimensional data of the eye could be exported via a memory device or over the internet and then be retrieved for use by the software program.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)

Abstract

La présente invention concerne un implant intraoculaire qui comprend une paroi latérale continue ayant une grande ouverture sur la partie inférieure et une petite ouverture sur la partie supérieure. L'implant est destiné à être positionné au-dessus de l'iris dans la chambre antérieure d'un œil en dessous de la cornée. L'implant est de préférence coloré afin de fournir une recoloration cosmétique de l'iris.
PCT/US2008/054458 2007-02-21 2008-02-20 Implant intraoculaire esthétique Ceased WO2008103754A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89090107P 2007-02-21 2007-02-21
US60/890,901 2007-02-21

Publications (2)

Publication Number Publication Date
WO2008103754A2 true WO2008103754A2 (fr) 2008-08-28
WO2008103754A3 WO2008103754A3 (fr) 2008-11-20

Family

ID=39710726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/054458 Ceased WO2008103754A2 (fr) 2007-02-21 2008-02-20 Implant intraoculaire esthétique

Country Status (1)

Country Link
WO (1) WO2008103754A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139394A2 (fr) 2010-04-26 2011-11-10 Ayhan Basoglu Diaphragme iris d'implant oculaire
CN101559009B (zh) * 2009-05-25 2012-06-06 四川省医学科学院（四川省人民医院） 带虹膜的角膜接触镜
JP2015530898A (ja) * 2012-08-07 2015-10-29 レーゲンアイ，エル．エル．シー． 虹彩角膜角度の狭窄を治療するための眼球用環状ステント
WO2020050785A1 (fr) * 2018-09-03 2020-03-12 Ayhan Basoglu Appareil de support d'implant permettant de réduire au minimum le contact entre l'implant oculaire et la surface de l'iris et permettant d'éliminer le contact entre l'implant oculaire et l'angle iridocornéen et également l'endothélium cornéen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811805B2 (en) * 2001-05-30 2004-11-02 Novatis Ag Method for applying a coating
ATE397425T1 (de) * 2002-09-24 2008-06-15 Carriazo Cesar C Dr Implantat zur änderung der iris-farbe
US7025781B2 (en) * 2003-01-31 2006-04-11 Delary Alberto Kahn Artificial iris diaphragm implant
US20050027354A1 (en) * 2003-07-28 2005-02-03 Advanced Medical Optics, Inc. Primary and supplemental intraocular lens

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101559009B (zh) * 2009-05-25 2012-06-06 四川省医学科学院（四川省人民医院） 带虹膜的角膜接触镜
WO2011139394A2 (fr) 2010-04-26 2011-11-10 Ayhan Basoglu Diaphragme iris d'implant oculaire
JP2013524994A (ja) * 2010-04-26 2013-06-20 ステラー デバイシーズ エルエルシー 眼内インプラント虹彩絞り
EP2563274A4 (fr) * 2010-04-26 2014-10-01 Devices Llc Stellar Diaphragme iris d'implant oculaire
JP2015530898A (ja) * 2012-08-07 2015-10-29 レーゲンアイ，エル．エル．シー． 虹彩角膜角度の狭窄を治療するための眼球用環状ステント
WO2020050785A1 (fr) * 2018-09-03 2020-03-12 Ayhan Basoglu Appareil de support d'implant permettant de réduire au minimum le contact entre l'implant oculaire et la surface de l'iris et permettant d'éliminer le contact entre l'implant oculaire et l'angle iridocornéen et également l'endothélium cornéen

Also Published As

Publication number Publication date
WO2008103754A3 (fr) 2008-11-20

Similar Documents

Publication Publication Date Title
CA2796608C (fr) Diaphragme iris d'implant oculaire
AU667342B2 (en) Corneal ring inlay and methods of use
US8603166B2 (en) Intraocular lens assembly
US20010018612A1 (en) Intracorneal lens
EP1001720B1 (fr) Lentille intra-corneenne diffractive
US6090141A (en) Small intracorneal lens
US5628794A (en) Multifocal corneal implant lens having a hydrogelo coating
US7326246B2 (en) Accommodating intraocular lens with elongated suspension structure
US6398809B1 (en) Intraocular lens
US10952630B2 (en) Device for electrophysiological recording from the eye
US20040064182A1 (en) High-myopia anterior chamber lens of one-piece, foldable construction
EP2823789A1 (fr) Implant intraoculaire à petite ouverture (trou d'épingle) pour augmenter la profondeur d'un foyer
EA002534B1 (ru) Устройство для лечения дегенерации желтого пятна
JPH08504115A (ja) 角膜湾曲調整用の重なりリングデバイス
JPH0219146A (ja) 眼科用レンズ
JPH07506014A (ja) 角膜の湾曲を変えるための方法
CN101636197A (zh) 用于固定角膜假体的方法和系统
JP2015526178A (ja) 眼内レンズ、特に毛様体眼内レンズ
JP2010520010A (ja) 眼内レンズ
CA2646831A1 (fr) Support de lentille intraoculaire
MX2015006085A (es) Diseño de borde para reducir efectos foticos no deseados en lentes intraoculares.
JPH08501009A (ja) 乱視矯正用の角膜実質内リング
WO2008103754A2 (fr) Implant intraoculaire esthétique
WO2015153291A1 (fr) Dispositifs pour le traitement intra-oculaire d'une erreur de réfraction
KR101718074B1 (ko) 안구내렌즈 지지체

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08730290

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08730290

Country of ref document: EP

Kind code of ref document: A2